1531 ET - Cellebrite's newly permanent chief executive, Thomas Hogan, took over the role on an interim basis in January, about a month after completing final treatments for Stage 4 non-Hodgkin's lymphoma. Hogan is in complete remission and has steadily regained his energy and stamina, Chairman Adam Clammer says on a call with analysts. Hogan had been the board's executive chairman since 2023 until his interim CEO appointment. "We were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy," Clammer says. "The board is unanimous in its conviction that Tom is the right individual to lead Cellebrite." Hogan says on the analyst call that he wouldn't have returned to work for any company other than Cellebrite, where he feels "the obligation to lead a company that truly makes the world a safer place every day." Shares rise 9.9% to $15.37. (dean.seal@wsj.com)
(END) Dow Jones Newswires
August 14, 2025 15:31 ET (19:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.